Suppr超能文献

青蒿琥酯耐药性——一种新出现的威胁。

Artesunate Resistance - An Emerging Threat.

机构信息

Kalinga Institute of Medical Sciences, Khorda.

出版信息

J Assoc Physicians India. 2022 Apr;70(4):11-12.

Abstract

UNLABELLED

Drug resistant malaria represents a challenging health problem in developing countries like India. The failure of drug artemisinin, which is the cornerstone of malaria therapy will rapidly compromise the treatment and prognosis of malaria. Resistance should be suspected if inspite of full treatment with Artesunate Combination Therapy and with no history of vomiting or diarrhoea, there is no clinical or parasitological response in the patient after 72 hours. The emergence of partial artemisinin resistant parasites were previously reported from West Bengal in the form of resistance to drugs. Presence of mutations in molecular markers was reported from different parts of India (Uttar Pradesh,Andhra Pradesh,Odisha and Jharkhand).

MATERIAL

We report four cases of complicated malaria in Eastern India between January 2020 and July 2021, with apparent treatment failure with artemisinin drugs. Case1 A 45 old male known diabetic and hypertensive presenting with fever with loose stools since 5 days and seizures since 1 day. Case 2 A 59 year old male patient, known diabetic admitted with fever,black stools and decreased urination for 10 days. Case 3 A 35 year old male patient admitted with fever, headache, vomiting and hematuria for 5 days. Case 4 A 25 year old pregnant female admitted with complaints of bleeding per vaginum since 10 days with fever and vomiting for 6 days. In all cases malaria was confirmed with rapid card test and peripheral smears showed ring forms of plasmodium falciparum.Parasite levels were estimated to be between 30% to 45% in all cases.The patients were treated with injectable artesunate and once they tolerated oral medication they were started on oral artesunate combination therapy.

OBSERVATION

After 4 days repeat peripheral smears showed persistence of parasites. Organ dysfunction did not subside. Hence Injectable Quinine and clindamycin was started in all cases. On day 7 all obtained microscopic parasite clearance. Cases 2 and 4 attained complete recovery,but the other two cases developed multiorgan dysfunction followed by septic shock and succumbed on 11th and 14th day of admission respectively. We could not confirm artemisinin resistance in any of these cases due to lack of availability of gene testing in our area.

CONCLUSION

This report emphasizes the need for increased surveillance to identify artemisinin resistance in India. It will aid the treating physician for more selective use of drug-combinations which are less likely to foster resistance.

摘要

未加标签

耐药疟疾是印度等发展中国家面临的一个具有挑战性的健康问题。如果青蒿素类药物(青蒿琥酯联合疗法的基石)治疗失败,且患者无呕吐或腹泻病史,但在 72 小时后仍无临床或寄生虫学反应,应怀疑出现耐药。此前,西孟加拉邦曾报告青蒿素类药物耐药的寄生虫部分耐药。印度不同地区(北方邦、安得拉邦、奥里萨邦和恰尔康得邦)也报告了分子标志物突变的存在。

材料

我们报告了 2020 年 1 月至 2021 年 7 月期间印度东部的 4 例复杂疟疾病例,这些病例显然对青蒿素类药物治疗失败。病例 1:一名 45 岁的男性,患有糖尿病和高血压,发热伴稀便 5 天,抽搐 1 天。病例 2:一名 59 岁男性,患有糖尿病,因发热、黑便和少尿 10 天入院。病例 3:一名 35 岁男性患者,因发热、头痛、呕吐和血尿 5 天入院。病例 4:一名 25 岁孕妇,因阴道出血 10 天伴发热和呕吐 6 天入院。所有病例均通过快速卡片检测确诊为疟疾,外周血涂片显示恶性疟原虫环状体。所有病例的寄生虫水平估计在 30%至 45%之间。患者接受了青蒿琥酯注射治疗,一旦能够耐受口服药物,即开始口服青蒿琥酯联合治疗。

观察

重复外周血涂片显示 4 天后仍有寄生虫存在。器官功能未改善。因此,所有患者均开始使用注射用奎宁和克林霉素。第 7 天,所有患者均获得了显微镜下寄生虫清除。病例 2 和 4 完全康复,但另外两例出现多器官功能障碍,随后发生感染性休克,分别于入院第 11 天和第 14 天死亡。由于我们所在地区缺乏基因检测,因此无法确定这些病例是否存在青蒿素耐药性。

结论

本报告强调需要加强监测,以确定印度的青蒿素耐药性。这将有助于治疗医生更有针对性地使用不太可能产生耐药性的药物组合。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验